{
  "docId": "019de073-9e32-71bd-acba-301a2d9cbf00",
  "docSlug": "d469b8223f6f86cb5d6a1f0a99cbce5c",
  "documentTitle": "Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 2,
  "pageCount": 28,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "disclaimer",
  "function": "front_matter",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Includes a specific disclosure regarding Dr. Harvey Levy's role as a Principal Investigator and Consultant.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9e32-71bd-acba-301a2d9cbf00/2",
  "deckHref": "/decks/019de073-9e32-71bd-acba-301a2d9cbf00",
  "deckJsonHref": "/decks/019de073-9e32-71bd-acba-301a2d9cbf00.json",
  "deckAnchorHref": "/decks/019de073-9e32-71bd-acba-301a2d9cbf00#slide-2",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.864,
        "x": 0.068,
        "y": 0.148
      },
      "kind": "disclaimer",
      "text": "This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fc9da10-9c4b-4e2e-bf12-438b686f07a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.864,
        "x": 0.068,
        "y": 0.895
      },
      "kind": "paragraph",
      "text": "Dr. Harvey Levy is the Principal Investigator of the Boston site for the clinical trial of an enzyme replacement therapy for Homocystinuria sponsored by Travere and is Consultant to Aeglea on their clinical trial of a human enzyme therapy for Homocystinuria.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee9df878-2a08-4f0d-ba67-fdc517286ae1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.335,
        "x": 0.068,
        "y": 0.048
      },
      "kind": "title",
      "text": "Forward Looking Statements",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "747733c8-f0b6-42a9-ada3-7ca6b2854a2c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}